Sprint Bioscience AB (publ) summarizes below the company's upcoming meetings with potential partners and investors during the spring of 2025. In addition, the company will present at international scientific conferences. Information will be provided continuously, and the list may be updated.
For investors:
January 22
Redeye Fight Cancer, Stockholm, Sweden
https://www.redeye.se/events/1052608/redeye-theme-fight-cancer
March 13
Swiss Nordic Bio, Zürich, Switzerland
https://www.swissnordicbio.com/
International partnering conferences:
March 17-19
BIO-Europe, Milan, Italy
https://informaconnect.com/bioeurope-spring/
June 16 -19
BIO International Convention, Boston, USA
https://convention.bio.org/bio-2025
For further information, kindly contact:
Johan Emilsson, CEO, Sprint Bioscience
Tel: +46 (8) 411 44 55
Epost:johan.emilsson@sprintbioscience.com
About Sprint Bioscience AB (publ)
Sprint Bioscience develops small molecule first-in-class drug programs with a focus on oncology. With a fragment-based drug development method, the company develops drug programs in a time- and resource-efficient manner. The programs are out-licensed to global pharmaceutical companies during the pre-clinical phase and the company has successfully entered into several license agreements. The Sprint Bioscience share is listed on the Nasdaq First North Premier Growth Market and trades under the ticker symbol SPRINT. The company is based in Stockholm with operations located in Huddinge. Further information is available on the company's website; www.sprintbioscience.com. Certified Advisor is FNCA Sweden AB, www.fnca.se.
